{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:22:13Z","timestamp":1715386933051},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,9]]},"DOI":"10.7759\/cureus.60003","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:11:57Z","timestamp":1715310717000},"source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia Gravis-Like Syndrome Resulting From Immune Checkpoint Inhibitors in a Patient With Urothelial Carcinoma"],"prefix":"10.7759","author":[{"given":"Alvaro  J","family":"Vivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Punchayil Narayanankutty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Lamarche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Amin Kashani S, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00372-8","article-title":"Increasing cure rates of solid tumors by immune checkpoint inhibitors","volume":"12","author":"Ma W","year":"2023","unstructured":"Ma W, Xue R, Zhu Z, et al.. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023, 12:10. 10.1186\/s40164-023-00372-8","journal-title":"Exp Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin Q","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al.. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023, 14:1167975. 10.3389\/fimmu.2023.1167975","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang YT","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020, 11:10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030655","article-title":"Assessing the future of solid tumor immunotherapy","volume":"10","author":"Guha P","year":"2022","unstructured":"Guha P, Heatherton KR, O'Connell KP, Alexander IS, Katz SC. Assessing the future of solid tumor immunotherapy. Biomedicines. 2022, 10:655. 10.3390\/biomedicines10030655","journal-title":"Biomedicines"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma P","year":"2019","unstructured":"Sharma P, Siefker-Radtke A, de Braud F, et al.. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results. J Clin Oncol. 2019, 37:1608-16. 10.1200\/JCO.19.00538","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","author":"Fecher LA","year":"2013","unstructured":"Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013, 18:733-43. 10.1634\/theoncologist.2012-0483","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi E","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A, et al.. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology. 2020, 95:e2442-52. 10.1212\/WNL.0000000000010632","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia A","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al.. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021, 384:1529-41. 10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities","volume":"26","author":"Spring LM","year":"2021","unstructured":"Spring LM, Nakajima E, Hutchinson J, et al.. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021, 26:827-34. 10.1002\/onco.13878","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1276976","article-title":"Assessing real-world safety concerns of sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system","volume":"13","author":"Gui X","year":"2023","unstructured":"Gui X, Zhao J, Ding L, et al.. Assessing real-world safety concerns of sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system. Front Oncol. 2023, 13:10.3389\/fonc.2023.1276976","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184494","article-title":"Pathophysiology of immune checkpoint inhibitor-induced myocarditis","volume":"14","author":"Jim\u00e9nez-Alejandre R","year":"2022","unstructured":"Jim\u00e9nez-Alejandre R, Ruiz-Fern\u00e1ndez I, Mart\u00edn P. Pathophysiology of immune checkpoint inhibitor-induced myocarditis. Cancers (Basel). 2022, 14:4494. 10.3390\/cancers14184494","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann SC","year":"2019","unstructured":"Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford). 2019, 58:vii59-67. 10.1093\/rheumatology\/kez308","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi J","year":"2020","unstructured":"Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020, 20:e9. 10.4110\/in.2020.20.e9","journal-title":"Immune Netw"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250030-myasthenia-gravis-like-syndrome-resulting-from-immune-checkpoint-inhibitors-in-a-patient-with-urothelial-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:12:00Z","timestamp":1715310720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250030-myasthenia-gravis-like-syndrome-resulting-from-immune-checkpoint-inhibitors-in-a-patient-with-urothelial-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.60003","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}